These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12858351)

  • 1. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
    Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
    Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo.
    Gawronska B; Leuschner C; Enright FM; Hansel W
    Gynecol Oncol; 2002 Apr; 85(1):45-52. PubMed ID: 11925119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
    Hansel W; Leuschner C; Enright F
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):26-33. PubMed ID: 17382461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting breast and prostate cancers through their hormone receptors.
    Leuschner C; Hansel W
    Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates.
    Hansel W; Leuschner C; Gawrońska B; Enright F
    Reprod Biol; 2001 Jul; 1(1):20-32. PubMed ID: 14666172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
    Leuschner C; Enright FM; Gawronska B; Hansel W
    Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
    Hansel W; Enright F; Leuschner C
    Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.
    Zaleska M; Bodek G; Jana B; Hansel W; Ziecik AJ
    Exp Clin Endocrinol Diabetes; 2003 May; 111(3):146-53. PubMed ID: 12784188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.
    Vuorenoja S; Rivero-Müller A; Ziecik AJ; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2008 Jun; 15(2):635-48. PubMed ID: 18509010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors.
    Leuschner C; Enright FM; Melrose PA; Hansel W
    Prostate; 2001 Feb; 46(2):116-25. PubMed ID: 11170139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hecate-CGbeta conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-alpha promoter.
    Vuorenoja S; Mohanty BP; Arola J; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2009 Jun; 16(2):549-64. PubMed ID: 19261682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
    Rivero-Müller A; Vuorenoja S; Tuominen M; Wacławik A; Brokken LJ; Ziecik AJ; Huhtaniemi I; Rahman NA
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):17-25. PubMed ID: 17363137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
    Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.